Impact of cladribine on soluble adhesion molecules in multiple sclerosis

Authors


Krystyna Mitosek-Szewczyk, Department of Neurology, Medical University in Lublin, ul. Jaczewskiego 8, 20-954 Lublin, Poland
Tel.: +48 817244720
Fax: +48 817244540
e-mail: krystyna.mitosek@am.lublin.pl

Abstract

Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, Belniak E. Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Acta Neurol Scand: 2010: 122: 409–413.
© 2010 The Authors Journal compilation © 2010 Blackwell Munksgaard.

Background –  Soluble forms of vascular cell adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1) and E-Selectin play a role in the regulation of blood–brain barrier damage and represent markers of the clinical course of multiple sclerosis (MS) and magnetic resonance imaging activity. We determined sICAM, sVCAM and sE-Selectin concentrations in the cerebrospinal fluid (CSF) and serum of patients with remitting–relapsing multiple sclerosis before and after cladribine treatment as well as in a control group.

Methods –  We examined 17 patients diagnosed according to McDonald’s criteria. Thirteen healthy age-matched subjects served as controls. The ELISA method was used to measure sICAM-1, sVCAM-1 and sE-Selectin.

Results –  The concentration of sICAM and sE-Selectin decreased in sera (difference between patients and controls was statistically significant, in the former P < 0.04, in the latter P < 0.0003) but not in the CSF of MS patients after cladribine treatment.

Conclusions –  The reduction in sICAM and sE-Selectin concentrations after cladribine treatment indicates an immuno-suppressive effect of the drug. The changes in levels of sICAM and sE-Selectin after cladribine treatment reflect disease activity and indicate a reduction in the inflammatory reaction.

Ancillary